Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
LA JOLLA PHARMACEUTICAL CO (LJPC) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/22/2022 8-K Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa...
Docs: "Amended and Restated Certificate of Incorporation of La Jolla Pharmaceutical Company",
"Amended and Restated Bylaws of La Jolla Pharmaceutical Company"
07/11/2022 8-K Quarterly results
02/16/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
11/18/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "La Jolla Pharmaceutical Company Announces Share Repurchase Plan"
07/27/2021 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
01/12/2021 8-K Quarterly results
12/18/2020 8-K Termination of a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
11/05/2020 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
Docs: "Letter from Squar Milner, LLP"
10/30/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
10/13/2020 8-K/A Quarterly results
10/02/2020 8-K Quarterly results
09/17/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/11/2020 8-K Quarterly results
07/28/2020 8-K Quarterly results
06/29/2020 8-K Quarterly results
06/24/2020 8-K Quarterly results
06/22/2020 8-K Quarterly results
06/02/2020 8-K Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm...
05/27/2020 8-K Other Events
05/12/2020 8-K Quarterly results
05/06/2020 8-K Quarterly results
04/29/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "LA JOLLA PHARMACEUTICAL COMPANY BYLAWS SECTION 1. OFFICES Section 1.1 Principal Executive Office. The Board of Directors shall fix the location of the principal executive office of the Corporation at any place within or outside the State of California. If the principal executive office is located outside the State of California, and the Corporation has one or more business offices in the State of California, the Board of Directors shall fix and designate a principal business office in the State of California. The location of the principal executive office and the principal business office in the State of California may be changed at any time by the Board of Directors. SECTION 2. SHAREHOLDERS"
03/13/2020 8-K Quarterly results
01/10/2020 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "La Jolla Pharmaceutical Company Announces Preliminary GIAPREZA™ Net Sales for the Three and Twelve Months Ended December 31, 2019"
12/23/2019 8-K Quarterly results
12/06/2019 8-K Cost Associated with Exit or Disposal Activities
11/29/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "La Jolla to Reassess Continued Development of LJPC-401 Based on Recent Clinical Results SAN DIEGO, CA - November 25, 2019 - La Jolla Pharmaceutical Company , a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that it will reassess continued development of LJPC-401 based on recent mixed clinical results. The Company plans to discontinue Study LJ401-BT01 due to lack of efficacy. Study LJ401-BT01 is a pivotal, multinational, multicenter, randomized, controlled study with a target enrollment of approximately 100 patients that is designed to evaluate the safety and efficacy of LJPC-401 as a treatment for iron overload in beta thalassemia patients who..."
10/11/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/07/2019 8-K Quarterly results
05/06/2019 8-K Quarterly results
Docs: "La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2019 and Highlights Recent Corporate Progress SAN DIEGO, CA - May 6, 2019 - La Jolla Pharmaceutical Company , a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three months ended March 31, 2019 and highlighted recent corporate progress. For the three months ended March 31, 2019, GIAPREZA net product sales were $4.4 million, compared to $0.8 million for the same period in 2018. La Jolla launched GIAPREZA in the U.S. in March 2018. La Jolla’s net loss for the three months ended March 31, 2019 was $31.7 million, or $1.17 per s..."
03/04/2019 8-K Quarterly results
Docs: "La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2018 and Highlights Recent Corporate Progress and Key Objectives SAN DIEGO, CA - March 4, 2019 - La Jolla Pharmaceutical Company , a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and twelve months ended December 31, 2018 and highlighted recent corporate progress and key objectives. Recent Corporate Progress and Key Objectives GIAPREZA TM"
01/07/2019 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "La Jolla Pharmaceutical Company Highlights Recent Corporate Progress and Key Objectives - Fourth-Quarter 2018 Net Sales of GIAPREZA Were Approximately $4.2 Million, Up 20% from the Third Quarter of 2018 - - Full-Year 2019 Net Sales Guidance for GIAPREZA of $24 Million to $28 Million - - Decision on GIAPREZA MAA by EMA Expected in June of 2019 - - NDA Planned for New Investigational Product, LJPC-0118, for the Treatment of Severe Malaria, in Fourth Quarter of 2019 - -Topline Results of Phase 2 Study of LJPC-401 in Patients with Hereditary Hemochromatosis Expected in Second Half of 2019- - Topline Results of Pivotal Study of LJPC-401 in Patients with Beta Thalassemia Expected in Mid-2020 - SAN DIEGO, CA - January 7, 2019 - La Jolla Pharmaceutical Company , a leader in the discovery, developm..."
10/24/2018 8-K Quarterly results
Docs: "La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2018 SAN DIEGO, CA - October 24, 2018 - La Jolla Pharmaceutical Company , a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and nine months ended September 30, 2018. For the three months ended September 30, 2018, GIAPREZA™ net product sales were $3.5 million. This compares to $1.6 million for the three months ended June 30, 2018 and $0.8 million for the three months ended March 31, 2018. La Jolla launched GIAPREZA in the U.S. in March 2018. For the nine months ended September 30, 2018, GIAPREZA net ..."
09/17/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy